BEGIN:VCALENDAR VERSION:2.0 PRODID:-//DTU.dk//NONSGML DTU.dk//EN CALSCALE:GREGORIAN BEGIN:VEVENT DTSTART:20200407T110000Z DTEND:20200407T140000Z SUMMARY:PhD defence by Esben Christensen X-ALT-DESC;FMTTYPE=text/html:
On 7 April, PhD student Esben Christensen will defend his PhD thesis "Preclinical Evaluation of Drug Delivery Systems for Immunotherapy"
\nPlease notice that the PhD defence will be live streamed via Zoom Video Conferencing.
\nDirect link for the meeting: PhD defence, Esben Christensen
\nPrincipal supervisor: Professor Thomas Lars Andresen
\nCo-supervisor: Senior Researcher Ladan Parhamifar
Evaluation Board
\nProfessor Sine Reker Hadrup, DTU Health Tech
\nJunior Group Leader Daniel H. Madsen, Herlev Hospital
\nHead of research unit Alexandre Corthay, Oslo University Hospital
Chairperson
\nAssociate Professor Jonas Rosager Henriksen
\nAbstract:
\nWithin the advancements in anti-cancer treatment, immunotherapy has shown highly encouraging results. Despite immune cells’ ability to recognize and kill cancer cells they are often suppressed in tumors. Immunotherapy can activate and teach the immune cells to recognize and kill cancer cells. However, due to high potential for cell-damage by activated immune cells the effects of immunotherapies must be as contained in tumors as much as possible.
\nIn this PhD thesis, we have provided a toolbox for other cancer researchers to better select relevant cancer models for preclinical testing of anti-cancer therapies. Additionally, we evaluated liposomes and micelles as nanoparticle drug delivery system for potentiating the anti-cancer effects of TLR7 agonists (immunotherapy). We demonstrate significant limitations for liposomes containing TLR agonists and encouraging preclinical anti-cancer results when formulating TLR7 agonists in micelles.